Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 10/20 | 0.69 |
| ▸ | ADH5 | P11766 | 1/20 | 0.67 |
| ▸ | RPA1 | P27694 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203130 | 0.93 | XDH (0.66) | XDHADH5RPA1ATMTP53 | |
| SCHEMBL12203133 | 0.90 | XDH (0.61) | XDHADH5RPA1ATM | |
| SCHEMBL1249134 | 0.86 | XDH (0.78) | XDHADH5GPR35 | |
| SCHEMBL12203132 | 0.86 | ADH5 (0.63) | XDHADH5RPA1ATMTP53 | |
| SCHEMBL1250214 | 0.84 | EPHX2 (0.56) | XDHADH5TP53GPR35 | |
| SCHEMBL7350821 | 0.83 | MEN1 (0.62) | XDH | |
| SCHEMBL9984638 | 0.83 | ADH5 (0.95) | XDHADH5RPA1ATMTP53 | |
| SCHEMBL17963197 | 0.83 | XDH (0.67) | XDHADH5RPA1ATMTP53 | |
| SCHEMBL6040548 | 0.83 | XDH (0.96) | XDHADH5RPA1ATMTP53 | |
| SCHEMBL17208852 | 0.82 | ADH5 (0.75) | XDHADH5RPA1ATMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059469-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS AKT INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20230365598-A1 | DEFLUORINATION OF ORGANO-FLUORINE MOLECUELS BY RARE-EARTH IONS RESULTING IN FLUORO-BRIDGED METAL-ORGANIC FRAMEWORKS | UNIV TEXAS (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365598-A1 | DEFLUORINATION OF ORGANO-FLUORINE MOLECUELS BY RARE-EARTH IONS RESULTING IN FLUORO-BRIDGED METAL-ORGANIC FRAMEWORKS | UNIV TEXAS (US) | 2023-11-16 | — | — | US | disclosed |
| US-10752643-B2 | Tunable rare-earth fcu-metal-organic frameworks | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2020-08-25 | — | — | US | disclosed |
| US-10752643-B2 | Tunable rare-earth fcu-metal-organic frameworks | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2020-08-25 | — | — | US | disclosed |
| US-10703767-B2 | — | — | 2020-07-07 | — | — | US | disclosed |
| US-10703767-B2 | — | — | 2020-07-07 | — | — | US | disclosed |
| US-20190185491-A1 | TUNABLE RARE-EARTH FCU-METAL-ORGANIC FRAMEWORKS | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2019-06-20 | — | — | US | disclosed |
| US-10253048-B2 | Tunable rare-earth fcu-metal-organic frameworks | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2019-04-09 | — | — | US | disclosed |
| US-10253048-B2 | Tunable rare-earth fcu-metal-organic frameworks | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2019-04-09 | — | — | US | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| CN-1558762-A | Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer | ŵ��Ų�ڿ˹�˾ | 2004-12-29 | — | — | CN | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| EP-1429763-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003027081-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185491-A1 | TUNABLE RARE-EARTH FCU-METAL-ORGANIC FRAMEWORKS | ORC3, POF1B, MB | XDH 3061/4885ADH5 4263/4885RPA1 218/4885 |
| US-10253048-B2 | Tunable rare-earth fcu-metal-organic frameworks | HNRNPU, FES, MCU | XDH 3919/4885ADH5 4276/4885RPA1 948/4885 |
| US-10703767-B2 | — | MB, ORC3, OR10J3 | XDH 2663/4885ADH5 4154/4885RPA1 540/4885 |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | XDH 4061/4885ADH5 4662/4885RPA1 560/4885 |
| US-20230365598-A1 | DEFLUORINATION OF ORGANO-FLUORINE MOLECUELS BY RARE-EARTH IONS RESULTING IN FLUORO-BRIDGED METAL-ORGANIC FRAMEWORKS | PFAS, MIA3, FUBP3 | XDH 3343/4885ADH5 1000/4885RPA1 2184/4885 |
| US-10752643-B2 | Tunable rare-earth fcu-metal-organic frameworks | ORC3, POF1B, MB | XDH 3061/4885ADH5 4263/4885RPA1 218/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | XDH 4464/4885ADH5 4777/4885RPA1 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.